|
Omega Therapeutics, Inc. (OMGA) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Omega Therapeutics, Inc. (OMGA) Bundle
Gewinnen Sie mit unserem leistungsstarken DCF -Taschenrechner Einblicke in Ihre Omega Therapeutics, Inc. (OMGA) -Schanganalyse! Mit dieser Excel -Vorlage können Sie mit realen Daten für (OMGA) ausgestattet werden, um Prognosen und Annahmen anzupassen, um den inneren Wert von Omega Therapeutics, Inc. genau zu bestimmen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .1 | 2.1 | 3.1 | 4.2 | 5.8 | 8.0 | 11.0 | 15.1 |
| Revenue Growth, % | 0 | 0 | 0 | 1339.58 | 49.25 | 37.31 | 37.31 | 37.31 | 37.31 | 37.31 |
| EBITDA | -16.5 | -27.5 | -64.6 | -97.6 | -93.5 | -.8 | -1.2 | -1.6 | -2.2 | -3.0 |
| EBITDA, % | 100 | 100 | -44892.36 | -4706.99 | -3021.65 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .8 | 1.1 | 1.4 | 5.2 | 6.8 | 4.2 | 5.8 | 8.0 | 11.0 | 15.1 |
| Depreciation, % | 100 | 100 | 963.19 | 250.36 | 218.84 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -17.3 | -28.6 | -66.0 | -102.8 | -100.3 | -.8 | -1.2 | -1.6 | -2.2 | -3.0 |
| EBIT, % | 100 | 100 | -45855.55 | -4957.36 | -3240.5 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 2.3 | 23.0 | 225.3 | 70.6 | 73.4 | 4.2 | 5.8 | 8.0 | 11.0 | 15.1 |
| Total Cash, percent | .0 | .0 | .2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .2 | .5 | 1.8 | 7.0 | 4.1 | 5.7 | 7.8 | 10.7 | 14.7 |
| Account Receivables, % | 100 | 100 | 361.81 | 86.73 | 225.79 | 97.35 | 97.35 | 97.35 | 97.35 | 97.35 |
| Inventories | .0 | .0 | -.3 | 41.2 | .3 | 1.8 | 2.4 | 3.4 | 4.6 | 6.3 |
| Inventories, % | 100 | 100 | -183.33 | 1985.09 | 9.79 | 41.96 | 41.96 | 41.96 | 41.96 | 41.96 |
| Accounts Payable | .9 | 1.1 | 2.1 | 3.1 | 1.6 | 3.8 | 5.3 | 7.2 | 10.0 | 13.7 |
| Accounts Payable, % | 100 | 100 | 1464.58 | 149.88 | 52.36 | 90.47 | 90.47 | 90.47 | 90.47 | 90.47 |
| Capital Expenditure | -.9 | -1.8 | -1.5 | -1.4 | -2.9 | -2.2 | -3.0 | -4.2 | -5.7 | -7.8 |
| Capital Expenditure, % | 100 | 100 | -1018.75 | -66.57 | -92.73 | -51.86 | -51.86 | -51.86 | -51.86 | -51.86 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -17.9 | -29.4 | -66.9 | -102.7 | -100.3 | -.8 | -1.2 | -1.6 | -2.2 | -3.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -17.1 | -30.1 | -66.0 | -140.6 | -62.2 | 4.8 | .9 | 1.2 | 1.6 | 2.2 |
| WACC, % | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 9.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 2 | |||||||||
| Terminal Value | 79 | |||||||||
| Present Terminal Value | 63 | |||||||||
| Enterprise Value | 72 | |||||||||
| Net Debt | 60 | |||||||||
| Equity Value | 12 | |||||||||
| Diluted Shares Outstanding, MM | 54 | |||||||||
| Equity Value Per Share | 0.22 |
What You Will Get
- Real OMGA Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Omega Therapeutics’ future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive OMGA Data: Pre-filled with Omega Therapeutics’ historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax assumptions, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- User-Friendly Interface: Intuitive, organized, and tailored for both professionals and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based OMGA DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Omega Therapeutics' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial strategy.
Why Choose Omega Therapeutics, Inc. (OMGA)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Expert Team: A dedicated team of scientists and professionals driving research forward.
- Robust Pipeline: A diverse array of potential treatments in various stages of development.
- Commitment to Quality: Stringent standards ensure the highest levels of safety and efficacy.
- Collaborative Approach: Partnerships with leading institutions to enhance research and development.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world data.
- Researchers: Integrate cutting-edge models into academic studies or clinical research.
- Investors: Evaluate your own hypotheses and analyze valuation outcomes for Omega Therapeutics, Inc. (OMGA).
- Market Analysts: Enhance your analysis with a ready-to-use, customizable financial model.
- Healthcare Entrepreneurs: Discover how large biotech firms like Omega Therapeutics are evaluated in the market.
What the Template Contains
- Pre-Filled Data: Includes Omega Therapeutics, Inc.'s (OMGA) historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Omega Therapeutics, Inc.'s (OMGA) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.